Wyniki wyszukiwania - Biblioteka Nauki

1

K-ras gene mutation as an early prognostic marker of colon cance

100%

Szpon Ł. , Stal A. , Zawadzki M. , Lis-Nawara A. , Kielan W. , Grzebieniak Z. , Szpon Ł. , Stal A. , Zawadzki M. , Kelan W. , Grzebiak Z. , Lis-Nawara A.

Polish Journal of Surgery

|

2016

|

tom 88(1)

15-19

EN

Due to increased colorectal cancer incidence there is a necessity of seeking new both prognostic and prediction factors that will allow to evolve new diagnostic tests. K-ras gene seems to be such a factor and its mutations are considered to be an early marker of progression of colorectal cancer. The aim of the study was to find a correlation between K-ras gene mutation in patients with diagnosed colorectal cancer and selected clinical parameters. Material and methods. A total of 104 patients (41 women and 63 men) with diagnosed colorectal cancer were included in this study. The average age of male group was 68.3 and in female group – 65.9. Samples were taken from paraffine blocks with tissue from diagnosed patients and K-ras gene mutation were identified. Afterwards the statistical analysis was made seeking the correlation betweenK-ras gene mutation incidence and clinical TNM staging system, tumour localisation, histological type, sex, age. Results. K-ras gene mutations were detected in 20.1% of all colorectal cancers. Significantly higher rate of K-ras gene mutations were diagnosed among patients classified at stage I (40%), stage IIC (50%) and stage IV (50%) according to the TNM classification. Conclusions. The results of our study are compatible with other studies and indicate the correlation between K-ras gene mutation and colorectal cancer incidence. Identification of K-ras gene mutation may complement other diagnostic methods at early stage of colorectal cancer.

2

Assessment Of the surgical treatment results IN patients with colorectal cancer IN A district hospital versus treatment results IN A highly specialized center

100%

Ciesielski P. , Berut M. , Górnicki K. , Skoczylas J. , Gorajska M. , Żuk M. , Rutkowski A. , Dłubek J.

Polish Journal of Surgery

|

2016

|

tom 88(4)

188-195

EN

In Poland there there are about 15‑16 thousand cases of colon cancer per year. The health care system allows the treatment of patients with colorectal cancer in highly specialized hospitals, oncology centers and district hospitals. The results of treatment within different reference level differ. The aim of the study was to evaluate the results of surgical treatment of patients with colorectal cancer at a district hospitals compared with the results of highly specialized center. Material and methods. A retrospective study. The material consisted of 171 consecutively operated patients diagnosed with colorectal cancer treated in the Department of Surgery, District Hospital in Wołomin. The control group consisted of 200 patients treated surgically at the Department of General and Colorectal Surgery, University Hospital in Łódź. In both centers, the patients were operated on by surgeons with experience in operations on the large bowel. The demographic data, information on the type of indication (elective vs emergent), and the severity of the disease by AJCC / TNM scale were collected. In the district hospital there were patients with more advanced disease (p <0.001), older (p = 0.0001), and often operated under emergent indication (p = 0.0001). The telephone survey collected data on survival or the date of death of the patient and set the percentage of five-year survival. Results. The proportion of five-year survival in the study group and control group was respectively 46% and 71% (p <0.0001). The percentage of five-year survival among patients undergoing elective procedure in both centers were respectively for Wołomin and Łódź 58% and 73% (p = 0.008). The proportion of 5-year survival among “younger” patients (<70) was respectively in Wołomin and Łódź 64% and 81% (p = 0.004) for “older” patients with (> 70) 50% and 60% (p = 0.6747) Conclusions. Overall results of surgical treatment of patients with colorectal cancer in the district hospital are inferior to treatment results in a highly specialized center. The population treated in the district hospital is statistically significantly different in comparison to patients treated in highly specialized center. The following differences were captured: severity of the disease, age and type of indication (elective vs emergent). The diffrences has an influence on the outcomes. The five years survival for patients > 70 years undergoing elective procedure is not statistically different between the district hospital and highly specialized center.

3

Surgical site infection among patients after colorectal cancer surgery

100%

Banaszkiewicz Z. , Cierzniakowska K. , Tojek K. , Kozłowska E. , Jawień A.

Polish Journal of Surgery

|

2017

|

tom 89(1)

9-15

EN

Wstęp: Zakażenie miejsca operowanego występuje u 2,5–22,3% operowanych chorych. Jest ono wykładnikiem jakości leczenia na oddziałach zabiegowych i ma duży wpływ na jego koszt. Materiał i metodyka: Analizie poddano chorych, u których w obserwacji 30-dniowej wystąpiło zakażenie miejsca operowanego. Grupę wyjściową stanowiło 1581 chorych z rozpoznaniem raka jelita grubego poddanych zabiegowi operacyjnemu w jednym ośrodku. Kryteriami wyłączającymi z badania były: brak wiarygodnej dokumentacji leczenia (szpitalnego lub ambulatoryjnego) i zgon chorego przed 30. dniem po operacji bez rozpoznanego zakażenia miejsca operowanego. Analizę statystyczną wykonano przy użyciu programu Statistica 10. Wyniki: Powikłania pooperacyjne wystąpiły u 262 chorych (16,6%). Najczęściej występującym było zakażenie miejsca operowanego (198 pacjentów; 12,52%). Stwierdzono, że wystąpienie tego powikłania zależne było od zaawansowania klinicznego raka, wieku chorych, chorób współtowarzyszących (cukrzyca i choroby kardiologiczne). Ponadto zauważono, że powikłanie to występowało znamiennie częściej u chorych operowanych w trybie pilnym z powodu powikłań oraz u tych, u których wyłoniono stomię jelitową. Nie stwierdzono natomiast zależności wystąpienia tego powikłania od płci chorych i lokalizacji guza nowotworowego. Wniosek: U chorych po operacji raka jelita grubego największe zagrożenie wystąpienia zakażenia miejsca operowanego wystąpiło u chorych po 75. roku życia, obciążonych cukrzycą i chorobami kardiologicznymi, z dużym zaawansowaniem klinicznym raka, operowanych w trybie ostrego dyżuru, u których konieczne było wyłonienie stomii jelitowej (a szczególnie kolostomii).

4

Prevalence ofCryptosporidiumsp. In Patients with Colorectal Cancer

100%

Sulżyc-Bielicka V. , Kołodziejczyk L. , Jaczewska S. , Bielicki D. , Kładny J. , Safranow K.

Polish Journal of Surgery

|

2012

|

tom 84

|

nr 7

348-351

EN

Parasitic protozoans of the Cryptosporidium genus are intracellular intestinal parasites of mammals, causing cryptosporidiosis. Clinically, cryptosporidiosis manifests as chronic diarrhoea. Individuals with immune disorders, including those with neoplasms, are at risk of symptomatic invasion.The aim of the study was the evaluation of Cryptosporidium sp. prevalence in patients with diagnosed colorectal cancer.Material and methods. The studied group encompassed 87 patients with diagnosed colorectal cancer, undergoing surgery at the Department of General and Oncological Surgery, Pomeranian Medical University, in the years 2009-2010. Immunoenzymatic tests for Cryptosporidium sp. on faeces samples were performed with the use of commercial test kit, ProSpecT®Cryptosporidium Microplate Assay (Remel Inc).Results. The presence of Cryptosporidium sp. was found in 12.6% of studied patients with colorectal cancer. The performed statistical analysis did not reveal any correlation between Cryptosporidium sp. infection and gender, age, neoplasm advancement stage as per Astler-Coller scale, neoplasm differentiation grade, or neoplastic tumour localisation in relation to the splenic flexure.Conclusions. There was found high prevalence of Cryptosporidium sp. in patients with colorectal cancer. It was comparable to the prevalence reported for patients with immune deficiency.

5

The relationship between metronidazole concentration and clinicopathological parameters in patients with colon cancer: A pilot study

80%

Sadowska A. , Car H. , Rodziewicz L. , Cepowicz D. , Kędra B.

Progress in Health Sciences

|

2013

|

tom 3

|

nr 2

74-81

EN

Purpose: To evaluate the concentration of metronidazole (MTZ) and its hydroxy metabolite (MTZOH) in cancer tissue and adjacent normal tissue in colorectal cancer patients in correlation with clinicopathologic parameters. Material and methods: MTZ and MTZOH concentration were measured in tumor tissue and surrounding healthy tissue by LC-ESI-MS-MS method. Results: We found different concentration of MTZ and MTZOH in colorectal cancer and healthy tissue, however the results were not statistically significant. MTZ concentration was elevated in tumors located in rectum, in patients over 60 years old, in patients without metastases to regional lymph nodes (N0) while decreasing with increasing tumor size. Women accumulated greater amounts of MTZ in comparison to men. Conclusion: Comparison of the concentration of the drug and its metabolite in tumor and normal colon tissue shows its different reaction to MTZ. MTZ concentration in the tumor and normal colon tissue is sex-dependent.

6

Incidence, morbidity and 5-year survival of colorectal cancer patients in the Kujawsko-Pomorskie voivodship in 2005-2011, based on data from the National Health Fund

80%

Nowicki A. , Dahms S.

Polish Journal of Surgery

|

2018

|

tom 90(4)

1-8

EN

Introduction: Incidence, morbidity and 5-year survival rates illustrate the epidemiological situation of colorectal cancer and assess effectiveness of the treatment. In Poland, the National Health Fund is the payer of services. The data related to morbidity, incidence, and 5-year survival may be supplementary to the epidemiological data of the National Cancer Registry. Objective: Analysis of services granted by NHF in Bydgoszcz to persons with diagnosed colorectal cancer in 2006–2011 including the assessment of incidence, morbidity and 5-year survival of the population in the Kujawsko-Pomorskie province. Material and methods: The study analyzed the services recorded in the database of the National Health Fund in Bydgoszcz in 2006-2011 given to patients with colorectal cancer. The Kaplan-Meier method and the gambling rate were used to determine the probability of survival. Results: In 2006–2011, men were offered 10.1% more services than women. The most frequent services regarded colorectal cancer (48.9%), rectal cancer (43.8%) and esophageal cancer (7.2%). In total, 50410 services were provided. Despite increase in the number of women in the population, 388 more men died than women. The probability of survival was 46.8 % and 42.6% for men and women, respectively, furthermore 41.8%, 44.2% and 48.9% for colon cancer and esophageal and rectal folds cancer, respectively. Conclusions: In the Kujawsko-Pomorskie province during the period of 2006–2011, the number of diagnosed colorectal cancers increased as did the overall number of services provided. There was also a downward trend for the total number of services granted in relation to the increase in the number of new diagnosed cases. Incidence and morbidity rates were variable, gradually increasing in subsequent years and amounted to 59/100000 and 67/100000, 355/100000 and 408/100000 in 2010 and 2011, respectively. The probability of 5-year survival was 45.2%. Diagnosis of a disease in patients above 69 years of age increased the likelihood of death.

7

PTEN – clinical significance in colorectal cancer

80%

Copija A. , Waniczek D. , Walkiewicz K. , Głogowski Ł. , Augustyniak H. , Nowakowska-Zajdel E.

OncoReview

|

2016

|

tom 6

|

nr 2

A86-90

EN

Phosphatase and tensin homolog deleted on chromosome ten (PTEN) is a human suppressor gene. Its protein product is a bispecific phosphatase playing the complex role in the cell cycle regulating processes and apoptosis by the mechanism of signal transduction into the cell via tyrosine kinase B signaling pathway (PI3K/Akt/mTOR). Reduction or loss of PTEN function is implicated in the pathogenesis of many malignancies, including colorectal cancer. A gradual decrease in the function of PTEN in the sequence of transformations: normal tissue–polyp–adenocarcinoma – disseminated cancer was indicated. The relation between the PTEN loss and the higher clinical severity of colorectal cancer was observed, i.a. higher TNM status and higher tendency to form metastases, leading in some of the studies to shortened patients survival during the observation period. The potential predictive value of the PTEN function loss for the EGFR-targeted therapy in patients with advanced colorectal cancer is the subject of controversy. The potential application of PTEN assessment in clinical practice as a prognostic and/or predictive factor requires further well-designed prospective studies on larger patient population, using the unified methodology. The aim of the study is to summarize the current knowledge on the role of PTEN gene and PTEN protein in the pathogenesis of colorectal cancer and the role of PTEN in clinical practice.

8

Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer

80%

Orlikowska M.

OncoReview

|

2020

|

tom 10

|

nr 1

27-30

EN

Colorectal cancer is the second leading cause of cancer-related death worldwide. Trifluridine/tipiracil is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for, currently available therapies. In this report, we present a case of chemotherapy using trifluridine/tipiracil confirming the effectiveness of this drug primarily in the term of prolongation of progression free survival.

9

Carcinoembryonic antigen and matrix metalloproteinase 2 serum and peritoneal washes concentration in staging and prognosis in colorectal cancer patients

80%

Guzel T. , Mirowska-Guzel D. , Lech G. , Wroński M. , Iwanowska M. , Słodkowski M.

Polish Journal of Surgery

|

2018

|

tom 90(5)

36-43

EN

Purpose: The aim of the study was to determine the significance of carcinoembryonic antigen and matrix metalloproteinase 2 peritoneal washes and serum concentration in patients suffering from colorectal cancer concerning tumor staging and 5-year survival rate in these patients. Methods: 80 patients who underwent curative surgery for colorectal cancer were included in the study. Preoperative serum and intraoperative peritoneal washes CEA and MMP-2 concentrations were measured. Results: Regarding tumor penetration, CEA-s and CEA-p concentrations were higher in subsequent stages from T2 to T4. Both CEA-s and CEA-p concentrations were lower in T2 compared to T3 and T4. Significant difference of CEA-s and CEA-p was noted between T2 and T4 stages. MMP-2-s concentration was higher in T3 compared to T2, the highest MMP-2-p concentration was in T4, with no statistical significance. Regarding nodular status, a significant difference of CEA-s was noted between N0 and N1. For CEA-p, significance was found between N0 and N2 as between N1 and N2. MMP-2-s concentration was the highest in N1, MMP-2-p concentration was the highest in T4, with no statistical significance. The 5-year survival rate for all patients was 63.53%. There were significant differences in CEA-s and CEA-p concentrations between patients with negative and positive 5-year survival. Conclusion: Intraoperative peritoneal washes concentration of CEA may potentially serve as an important factor for more precise colorectal cancer staging. CEA-p and CEA-s concentrations correlate with survival rate in patients suffering from colorectal cancer and can be useful as an additional prognostic factor. The usefulness of MMP-2 measurement still requires further studies.

10

Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer

80%

Laczmanska I. , Sasiadek M. M.

Acta Biochimica Polonica

|

2011

|

tom 58

|

nr 4

467-470

EN

Phosphorylation and dephosphorylation processes catalyzed by numerous kinases and phosphorylases are essential for cell homeostasis and may lead to disturbances in a variety of vital cellular pathways, such as cell proliferation and differentiation, and thus to complex diseases including cancer. As over 80 % of all oncogenes encode protein tyrosine kinases (PTKs), protein tyrosine phosphatases (PTPs), which can reverse the effects of tyrosine kinases, are very important tumor suppressors. Alterations in tyrosine kinase and phosphatase genes including point mutations, changes in epigenetic regulation, as well as chromosomal aberrations involving regions critical to these genes, are frequently observed in a variety of cancers. Colorectal cancer (CRC) is one of the most common cancers in humans. CRCs occur in a familial (about 15 % of all cases), hereditary (about 5%) and sporadic (almost 75-80 %) form. As genetic-environmental interrelations play an important role in the susceptibility to sporadic forms of CRCs, many studies are focused on genetic alterations in such tumors. Mutational analysis of the tyrosine phosphatome in CRCs has identified somatic mutations in PTPRG, PTPRT, PTPN3, PTPN13 and PTPN14. The majority of these mutations result in a loss of protein function. Also, alterations in the expression of these genes, such as decreased expression of PTPRR, PTPRO, PTPRG and PTPRD, mediated by epigenetic mechanisms have been observed in a variety of tumors. Since cancer is a social and global problem, there will be a growing number of studies on alterations in the candidate cancer genes, including protein kinases and phosphatases, to determine the origin, biology and potential pathways for targeted anticancer therapy.

11

The influence of bowel preparation on postoperative complications in surgical treatment of colorectal cancer

80%

Małek Z. , Małek P. , Dziki Ł.

Polish Journal of Surgery

|

2019

|

tom 91(3)

10-14

EN

Introduction Colorectal cancer is the most common gastrointestinal cancer treated by departments and surgical clinics in Poland. Currently, the biggest challenge of surgery is to reduce the number of leaks in the bowel anastomoses and postoperative wound infections to a minimum. Objective Whether bowel preparation before surgery affects the early results of treatment? Methods The study was retrospective and included patients operated electively on one surgical center due to colorectal and rectal cancer in years 2013-2018. Patients who underwent surgery were divided into two groups in the study. The first was 109 patients with mechanical bowel irrigation. The second group of 118 patients, in addition to mechanical bowel preparation, received an oral antibiotic. Results The studied groups did not differ significantly in terms of traits that could affect the results of treatment within 30 days of surgery. Postoperative mortality was 0,9% and 0,85%. Complications: leakage of the bowel anastomosis 1,8% and 1,7%, postoperative obstruction 3,7% and 5,0%, wound dehiscence 2,75% and 0,85%, infection of the surgical site 13,8% and 3,4% respectively in the first and second group of patients. Conclusion 1. Mechanical bowel preparation in combination with the oral supply of antibiotic significantly reduces the frequency of surgical site infection compared to the mechanical rinsing itself. 2. Type of preparation of the intestine before the surgery does not significantly affect postoperative mortality and other complications, including anastomotic leak, but may be important for the frequency of postoperative wound dehiscence.

12

High expression of CD133 – stem cell marker for prediction of clinically agressive type of colorectal cancer

80%

Kostovski O. , Antovic S. , Trajkovski G. , Kostovska I. , Jovanovic R. , Jankulovski N.

Polish Journal of Surgery

|

2020

|

tom 92(3)

9-14

EN

Background: Colorectal cancer (CRC) is one of the most common malignancies in the world. The cancer stem cell (CSC) markers are associated with aggressive cancer types and poor prognosis. The objective of the study was to evaluate the CD133 expression and to correlate it with clinicopathological features in patients with CRC. Material and Methods: Our study included ninety patients with CRC who underwent curative surgical resection from 2012 to 2017 at the University Clinic for Digestive Surgery, Skopje, North Macedonia. Tumor samples were first analyzed with standard histopathological methods and then the CD133 expression was investigated immunohistochemically. The level of expression of CD133 was classified semiquantitatively. Low positivity was defined as positive immunoreactivity in <50% of tumor glands, and high positivity was defined as positive immunoreactivity in ≥50% of tumor glands. Furthermore, clinicopathological features of patients were retrospectively reviewed. Results: High expression of CD133 was found in 47.8% of patients’ CRC samples. In 69.6% of patients with metastatic lesions in visceral organs we found high expression of CD133. We found statistically significant differences in the expression of CD133 between patients with and without visceral metastatic lesions (P = 0.0153), between patients with a different T category (P = 0.0119), N status (P = 0.0066) and grade (G) (P = 0.0115). Our results showed that the stage of disease has the greatest impact on expression of CD133 (P < 0.00001). Conclusion: High expression of CD133 is a useful marker for prediction of the clinically aggressive type of CRC and can be routinely implemented in standard pathohistological diagnostics.

13

Unexpected domain composition of MACC1 links MET signaling and apoptosis

80%

Kokoszyńska K. , Kryński J. , Rychlewski L. , Wyrwicz L. S.

Acta Biochimica Polonica

|

2009

|

tom 56

|

nr 2

317-324

EN

Colorectal cancer, one of the most challenging malignancies, still has a limited number of recognized prognostic and predictive markers indicating appropriate treatment. MACC1 (metastasis-associated in colon cancer-1), a novel regulator of tumor growth and metastasis has recently been identified as an important prognostic factor of metastatic disease in colorectal cancer. The mechanism of MACC1 activity remains undetermined. Here we apply a combination of fold recognition and homology modeling algorithms to draft MACC1 function. The applied methods revealed that the MACC1 protein consists of four domains: ZU5, SH3, and two C-terminal death domains (DD). Previously a similar domain architecture (ZU5-DD) was observed in other proteins, involved mainly in signal transduction and apoptosis regulation. Based on the specific aspects of the closest homologues' biology functional hypotheses on MACC1 are proposed. A broad range of bioinformatic analyzes indicates that MACC1, besides its involvement in signal transduction from the MET receptor, links MET signaling and apoptosis.

14

Variability of clinical characteristic of colorectal cancer patients – analysis of selected parameters

80%

Copija A. , Głogowski Ł. , Walkiewicz K. , Janion K. , Nowakowska-Zajdel E.

OncoReview

|

2018

|

tom 8

|

nr 3

80-85

EN

Introduction: A steady increase of the incidence of colorectal cancer has been observed for over 30 years, particularly in well-developed countries. Colorectal cancer is one of the lifestyle-related neoplasms and depends on environmental factors. Aim: Aim of the study was to analyse selected clinical features of colorectal cancer patients. Material and methods: The study group consisted of 577 consecutive patients with colorectal cancer treated in the Department of Clinical Oncology in Bytom in 2006–2014. The patients were included into the study prospectively. The analysis of selected clinical, pathological and anthropometrical parameters was conducted. Results: The study group included 237 women and 341 men aged 26 to 86 years (mean age 64.3 ± 9.2 years). Primary tumours were mostly located in the colon and had histological grade 2. The surgical removal of the primary tumour was performed in 540 patients. 65 patients underwent preoperative radiotherapy, 201 – postoperative chemotherapy and 91 – postoperative radio-chemotherapy. 132 of patients obtained the first-line palliative chemotherapy. 88 of patients did not received oncological treatment. KRAS/RAS mutation were determined in 73 patients and the EGFR expression status in 53 patients. Conclusions: Colorectal cancer patients are a heterogeneous group with differential clinical, pathological and molecular features. 1. Therapeutic management of patients with colorectal cancer largely depends on its location, clinical and pathological stage, patients performance status and comorbidities. 2. Understanding the clinical features of patients with colorectal cancer becomes helpful in designing of screening, which take into account clinical profile of the patient, i.e. age, gender, comorbidities and anthropometric characteristics

15

Diabetes association of polyps and colon cancer

80%

Miłek T. , Forysiński K. , Myrcha P. , Ciostek P.

Polish Journal of Surgery

|

2019

|

tom 91(4)

9-12

EN

Aim: The aim of the study was to retrospectively assess the relationship between the occurrence of polyps and colon cancer in patients with type 2 diabetes. Methods: In 2014–2015, 976 colonoscopies were performed in patients. We compared the number of polyps with high-grade dysplasia and colorectal cancers in patients with and without diabetes. In addition, in the diabetic group we documented the relationship between HbA1C and the occurrence of polyps with high-grade dysplasia, and colon cancer. The data were statistically analyzed. Results: 1. Patients with diabetes show a higher incidence of polyps with high-grade dysplasia/carcinoma – 32/91 (35.16%) in comparison to patients without diabetes – 136/885 (15.37%), P < 0.001; 2. Patients with diabetes show a higher incience of polyps with cancer – 9/91 (9.89%) as compared to patients without diabetes – 18/885 (2.03%), P < 0.001. 3) Colorectal cancer occurred significantly more often in uncontrolled diabetes (P = 0.022). Conclusion: The conducted study shows a significant association between type 2 diabetes and the incidence of colorectal adenomas. These findings may lead to a conclusion that diabetic patients are at a higher risk of developing colorectal cancer, thus are in higher need for controlled colonoscopy. Therefore, it may be worth considering a scheme for screening patients in the above-mentioned group with colonoscopy.

16

The - 801 G/A Polymorphism ofCXCL12Promoter Gene as Unfavorable Genetic Prognosis factor involved in Colorectal Cancer

80%

Langner E. , Przybyłowska K. , Sygut A. , Mik M. , Dziki Ł. , Dziekiewicz M. , Majsterek I. , Dziki A.

Polish Journal of Surgery

|

2010

|

tom 82

|

nr 8

459-463

EN

CCXL12 also called stromal derived factor-1 (SDF-1), a protein related to angiogenesis and inflammation, has been correlated with the progression of a number of malignancies. Single nucleotide - 801G/A polymorphism of CXCL12 gene has been described and is regarded as a target for cis-acting factor that has the ability to up-regulate CXCL12 expression.The aim of the study. Based on the suggested role of CXCL12 in the pathogenesis of cancer we examined the association of the gene variant CXCL12-A with colorectal cancer.Material and methods. We genotyped - 801G/A polymorphism of CXCL12 gene in 164 colorectal patients and 184 age-matched healthy subjects. Genotyping was done with PCR-RFLP.Results. There were no significant differences in the frequencies of SDF1-3'A allele, between patients and controls. The frequency of CXCL12 G/A and G/A plus A/A genotype was significantly higher in a group of patients with lymph node metastasis compared with those without metastasis.Conclusions. The CXCL12 gene G/A polymorphism was not related to colorectal cancer risk but is associated with the induction of lymph-node metastasis of colorectal cancer disease in Polish.

17

Oxidative protein damage in patients with colorectal cancer

80%

Murlikiewicz Ł. , Sygut A. , Trzciński R. , Grzegorczyk K. , Rutkowski M. , Dziki A.

Polish Journal of Surgery

|

2010

|

tom 82

|

nr 8

454-458

EN

Colorectal cancer is a major public health concern particularly in developed countries. Despite decades of advances in the treatment and prevention of colorectal cancer, it remains the second most common cause of cancer death. There now exists convincing evidence that reactive oxygen species play an important role in the etiology and progression of a number of human diseases including colorectal cancer. Reactive oxygen species may damage all types of biological molecules. However, proteins are possibly the most immediate vehicle for inflicting oxidative damage on cells since they are often catalysts rather than stoichiometric mediators, hence, the effect of damage to one molecule is greater than stoi-chiometric.The aim of the study was to investigate oxidative protein damage in patients with colorectal cancer and its correlation with the clinical stage of the disease.Material and methods. The study group comprised 102 patients operated on for colorectal cancer in different clinical stages of the disease. Plasma carbonyl levels were determined using Levin's method.Results. Patients in all tumor groups showed significantly higher levels of plasma carbonyls when compared to healthy people. We observed an increase in mean plasma carbonyl levels correlating with an increase in the degree of disease advancement.Conclusions. This study demonstrates that reactive oxygen species may have a role in pathogenesis of colorectal cancer. The outcomes of this research seem to confirm that antioxidants may play a role in chemoprevention of colorectal cancer.

18

Complications of palliative antiangiogenic therapy in patients with colorectal cancer

80%

Domagała-Haduch M. , Jasiówka M. , Nowak Ł. , Cedrych I.

OncoReview

|

2016

|

tom 6

|

nr 4

A199-204

EN

Introduction: Bevacizumab is an antiangiogenic drug used in the therapy of numerous solid tumours including colorectal adenocarcinoma. The efficacy and safety of bevacizumab has been demonstrated in many multicenter clinical trials. The scope of this paper is to analyze the safety profile of bevacizumab in patients with stage IV colorectal cancer. Aim of the study: Analysis of toxicity and safety of the treatment with bevacizumab patients with colorectal cancer in the metastatic stage. Material and methods: Retrospective analysis of medical records of 42 patients with advanced colorectal cancer treated in the Department of Systemic and Generalized Malignancies, Maria Skłodowska-Curie Memorial Institute of Oncology, Kraków Branch, in the period 2007–2014. Results: The median time of treatment with bevacizumab was 6 months. The median duration of progression-free survival (PFS) was 8.5 months. Toxicity of treatment with bevacizumab affected 43 percent of patients. The most common adverse events observed was hypertension and bleeding. In 6 patients (14.3%) the treatment with bevacizumab was interrupted due to adverse events (thromboembolic events, bleeding and gastrointestinal perforation). Conclusions: Bevacizumab is a safe therapeutic option in patients with metastatic colorectal cancer, provided that patients are provided close oncological and general medical monitoring.

19

Risk factors in reoperations in colorectal surgery

80%

Zawadzki M. , Krzystek-Korpacka M. , Rząca M. , Czarnecki R. , Obuszko Z. , Sitarska M. , Witkiewicz W.

Polish Journal of Surgery

|

2019

|

tom 91(4)

13-18

EN

Background: Reoperations in colorectal surgery are usually a consequence of major surgical complications. Recently, the rate of reoperation has been proposed as a marker of surgical performance. Yet, the incidence of re-intervention varies significantly in literature, ranging from 5.2% to 13%. Therefore, in this study we investigated 30-day reoperation rates and made an attempt to identify risk factors of re-intervention following colorectal resection at our institution. Methods: This is a retrospective study of patients who had undergone colorectal resection at a single institution from 2013 to 2017. Univariate and multivariate analysis of predicting factors were performed. Results: Out of 464 patients included, 51 required reoperations (11%). The most common causes of reoperations were anastomotic leakage, postoperative bleeding, and wound dehiscence. In univariate analysis the age of the patient and location of the tumor were related to an increased rate of reoperation. In multivariate analysis patients older than 75 (OR = 2.1; 95%CI = 1.1–3.9) and tumors sited in the rectum (OR = 2.66; 95%CI = 1.4–5) were associated with an increased risk of re-intervention. Patients who required postoperative re-intervention stayed in hospital longer (14 vs. 6 days, P < 0.0001) and had higher mortality (9.8% vs. 1.2%, P = 0.002). Conclusions: Our study shows that reoperation rates that follow colorectal surgery are frequently undervalued. In our series, 11% of patients required an unplanned return to the operative room. Patient’s age and rectal tumors were the two independent factors that affect the rate of reoperation. Novel aspect: Data concerning reoperation rates in colorectal surgery is varying and most reports have shown the incidence of re-intervention to be as low as 5–7%. Our study demonstrates that reoperations after curative surgery for colorectal cancer are more frequent and may occur in over a tenth of total patients operated on.

20

Resections and Palliative Procedures in Patients Operated on for Colorectal Cancer in Poland in 2005-2008

80%

Klimczak A. , Mik M. , Dziki Ł. , Seroka W. , Dziki A.

Polish Journal of Surgery

|

2010

|

tom 82

|

nr 11

621-625

EN

The aim of the study was analysis of the number of resection and palliative procedures in patients operated on for colorectal cancer in Poland. We also analyzed the number of sphincter-sparing surgery in patients with rectal cancer.Material and methods. Statistical data about surgical procedures performed in patients with colorectal cancer were obtained from the National Institute of Hygiene in Warsaw. The procedures were divided into palliations and resections. The analysis was performed for the period from 2005 to 2008. We analyzed the data including women and men.Results. We observed an increase in the number of resections from 3381 to 3768 (85.6-88% of all treatments) (2005-2008) in patients with colon cancer. A similar regularity was observed in patients who underwent surgery for rectal cancer from 2335 to 2712, respectively (76.4 to 81.4% of all treatments). Similarly, the number of sphincter-sparing surgery over the course of the period has increased from 1502 to 1916 operations.Conclusions. The increase in the percentage of resections and sphincter-sparing surgery may indicate the progress in the earlier detection of colorectal cancer. Another reason for this increase may be improving the level of education of surgeons due to the better availability of workshops and training. However, analysis is based on too short period of time and these conclusions cannot be regarded as final.